Medical Cannabis Studies

• View All (505)

Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol (2013)

This research showed that using a cannabis extract with high content of cannabidiol (CBD) called (CBD) (BDS) botanical pharmacological substance (CBD). It can attenuate the carcinogenesis of the colon and prevent the reproduction of colorectal cancer cells by activating the CB1 and CB2 receptor. View study
Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor (2016)

This investigation shows that local administration of the selective CB2 agonist JWH-133 at 50 mg / day to Rag-22/2 mice induced a considerable regression of malignant tumors generated by the inoculation of C6 glioma cells. It could be observed in the experiments carried out with C6 glioma cells in culture, evidenced the internalization of the CB2 receptor but not the CB1 receptor after the challenge JWH-133 and showed that the selective activation of the CB2 receptor indicated the apoptosis through the synthesis Improved de novo ceramide View study
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors (2003)

This study aims to verify the inhibition of the growth of skin tumors and angiogenesis in vivo by activation of cannabinoid receptors. The results of this investigation give a new therapeutic approach for the treatment of skin tumors. View study
Inhibition of tumor angiogenesis by cannabinoids (2003)

Active angiogenesis is causally involved in the progression of most solid tumors. For this reason a great effort is being made in the development of effective antiangiogenic drugs to treat cancer. With respect to the study of the therapeutic effects of cannabinoids, the findings of this study show that these compounds can be considered promising anti-tumor agents, since they inhibit tumor angiogenesis and growth in vivo without significant side effects. However, more research is needed to elucidate these molecular mechanisms. View study
Integrating cannabis into clinical cancer care (2016)

Cannabis and cannabinoids are useful for controlling symptoms related to cancer and its treatment. Cannabinoids may be synergistic with opioids in pain relief. The safety profile of cannabis is acceptable, with side effects that are generally tolerable and of short duration. Preclinical data suggest that cannabinoids may have a direct antitumor activity. Oncologists could find cannabis and cannabinoids as effective tools to care for patients living with cancer and beyond it. However, in-depth human studies should be carried out in order to verify the effectiveness of cannabinoids in the treatment of cancer. View study
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews (2010)

This review was based on studying the potential of cannabigerol (CBG) to reverse the antiemetic and antiemetic effects of cannabidiol (CBD). Through the analysis of the results, it was concluded that the interactions between moderate doses of CBG and CBD can oppose each other in the 5-hydroxytryptamine 1A receptor (5-HT1A) in the regulation of nausea and vomiting. View study
Interaction Between The Protective Effects Of Cannabidiol And Palmitoylethanolamide In Experimental Model Of Multiple Sclerosis In C57BL/6 Mice (2015)

According to the results of this study, cannabidiol (CBD) and palmitoylethanolamide (PEA), non-psychoactive cannabinoids (CB), attenuate neurobehavioral deficits, histological damage and expression of inflammatory cytokines in animals immunized with glycoprotein oligodendrocyte myelin (MOG) ). View study
Interactions between cannabidiol and commonly used antiepileptic drugs (2017)

In this study, the possible interactions between cannabidiol (CBD) and common antiepileptic drugs (AED) were identified. View study
Interactions between delta9-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys (2012)

THC does not significantly improve the positive reinforcing effects of heroin, further supporting the view that the combination of cannabinoids and opioid receptor agonists does not increase, and may reduce the abuse of individual drugs. View study
Internet and computer based interventions for cannabis use: a meta-analysis (2013)

Computer-based and internet-based interventions as an approach to reduce the frequency of cannabis use. View study
Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis (2013)

Studies on the effectiveness of psychosocial interventions in patients with schizophrenia and cannabis use disorders. View study
Interventions for Atypical Facial Pain: A Review of Clinical Effectiveness and Guidelines [Internet] (2011)

Atypical facial pain (AFP), also known as persistent idiopathic facial pain (PIFP), is a chronic disorder involving lancinating pain located in the craniofacial region that is not characteristic of common cranial neuralgia and that does not It has apparent cause. The purpose of this report was to review available published literature related to pharmacological and non-pharmacological interventions for the treatment of atypical facial pain (AFP) in adults. View study